Hepatocelulární karcinom – možnosti radikální léčby

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Hepatocellular carcinoma - possibilities of the radical treatment
Authors

KALA Zdeněk KYSELA Petr PENKA Igor PROCHÁZKA Vladimír VÁLEK Vlastimil ANDRAŠINA Tomáš KISS Igor OSTŘÍŽKOVÁ Lenka

Year of publication 2011
Type Article in Periodical
Magazine / Source Farmakoterapie
MU Faculty or unit

Faculty of Medicine

Citation
Field Surgery incl. transplantology
Keywords hepatocellular carcinoma; surgical treatment; radical; liver transplantation; resection
Description HCC represents the sixth most frequent malignancy worldvide and is the third most frequent cause of tumour related death. Material and methods: A survey over causes, diagnostics and treatment methods has been conducted. Results: The development of HCC in non-cirrhotic liver is very rare. All patients with liver cirrhosis that is caused mainly by HBV and HCV infection should be screened with a plain liver US every 6 months. There is no use of AFP level in screening but in staging. HCC is the only tumour the diagnosis of which can be made upon dynamic imaging methods - ot comprises typical appearance of HCC at two different methods (CEUS, dynamic contrast MRI, dynamic CT) in tumour 1-2 cm in diameter or at the only one dynamic method when the diameter is above 2cm. Laesions smaller than 1cm are to be checked with US at 3 months intervals. Uncertain cases ought to be biopsied until positive result. The BCLC screening system seems to be a suitable staging tool. Surgery and liver transplantation do not seem to be concurent but rather complementary. TACE or RFA may help in nonresectable cases. Sorafenib has become a standard treatment for advanced HCC.

You are running an old browser version. We recommend updating your browser to its latest version.

More info